The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The 2022 Tandem Meetings | PD-1 blockade after progression on bispecific CAR-T therapy in R/R B-cell malignancies
Joanna Zurko, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of a study investigating the efficacy of PD-1 blockade after failure of bispecific anti-CD20, anti-CD19 CAR-T therapy in patients with R/R B-cell malignancies. Overall, the study suggested that treatment with pembrolizumab did not lead to sustained response to treatment, but further studies are required to confirm these findings. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
